This study uncovers a previously unrecognized non‐catalytic function of PRMT1 and highlights the PBX2‐PRMT1‐SWI/SNF‐IGF2BP2 axis as a potential therapeutic target for overcoming CBP resistance in HNSCC. Here, PBX2 is linked to head and neck squamous cell carcinoma.